metaPreg - Gabapentin (All indications) during pregnancy

Gabapentin (All indications) updated on 04-22-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.04 [0.52, 2.09]	0%	7 studies	49,653	474	not evaluable	ROB	-
Major congenital malformations	1.08 [0.53, 2.16]	0%	7 studies	49,648	474	not evaluable	ROB	-
Microcephaly / Small head circumference for gestational age	1.26 [0.18, 8.69]	57%	2 studies	134,493	1,701	not evaluable	ROB	-
Hypospadias	1.55 [0.31, 7.89]	0%	2 studies	3,378	396	not evaluable	ROB	-
Oro-facial clefts	2.18 [0.27, 17.84]	0%	2 studies	2,816	396	not evaluable	ROB	-
Bilateral renal agenesis including Potter syndrome	34.08 [2.11, 550.91]	-	1 study	75	365	not evaluable	ROB	67.65 [3.64; .]
Bladder exstrophy and/or epispadia	31.19 [1.93, 503.78]	-	1 study	82	365	not evaluable	ROB	61.87 [3.27; .]
Ebstein's anomaly	50.95 [3.14, 827.39]	-	1 study	50	365	not evaluable	ROB	101.40 [5.73; .]
Hypoplastic right heart (HRH/HRHS)	38.69 [2.39, 626.25]	-	1 study	66	365	not evaluable	ROB	76.88 [4.21; .]
Pulmonary valve atresia	16.87 [1.05, 271.48]	-	1 study	152	365	not evaluable	ROB	33.23 [1.27; .]
22 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	2.38 [1.79, 3.15]	0%	4 studies	91,697	453	not evaluable	ROB	4.19 [2.99; .]
Low birth weight (< 2500g)	1.76 [0.89, 3.49]	92%	2 studies	233,020	1,714	not evaluable	ROB	-
Small for gestational age (weight)	1.15 [1.00, 1.34]	0%	2 studies	613,856	1,714	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation	-	-	0 study					-
1 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths (as a whole or unspecified)	4.41 [0.49, 39.98]	0%	3 studies	3	17	not evaluable	ROB	-
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	4.64 [0.23, 93.20]	0%	2 studies	2	3	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
ASD (Autism spectrum disorder): Diagnosis	1.14 [0.76, 1.70]	36%	5 studies	81,040	2,772	not evaluable	ROB	-
ASD (Autism spectrum disorder): Diagnosis/Risk	1.14 [0.76, 1.70]	36%	5 studies	81,040	2,772	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk	1.20 [0.91, 1.58]	0%	3 studies	152,450	1,442	not evaluable	ROB	-
Cognitive developmental disorders/delay (3-6 years old)	0.94 [0.47, 1.87]	0%	3 studies	28,847	1,806	not evaluable	ROB	-
Neuro-developmental disorders (as a whole)	0.96 [0.44, 2.10]	32%	4 studies	10,475	1,345	not evaluable	ROB	-
Severe cognitive developmental delay (Mental retardation) (3-6 years old)	0.94 [0.47, 1.87]	0%	3 studies	28,847	1,806	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis	1.28 [0.86, 1.91]	31%	2 studies	152,450	1,428	not evaluable	ROB	-
Language disorders/delay	0.62 [0.36, 1.05]	0%	2 studies	72,028	392	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study